A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectives

Ss, Desai; Shah, AS; Prabhash, K.; Jambhekar, NA

doi:10.4103/0019-509x.117007

Cited by 31 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 of 62 articles were conducted in Asians (19 in Chinese, 13 in Japanese, 10 in Koreans and 1 in Indians), 12 articles in Caucasians (7 in Americans and 5 in Europeans) and 7 articles in multi-ethnic populations. 43 articles involved unselected populations [4], [8], [11], [12], [17]–[55], and 20 articles enrolled specific groups of NSCLC patients according to either clinicopathological characteristics or genetic makeup [46], [56]–[74], with one article [46] provided data from both unselected and selected NSCLC groups. A flow diagram schematizing the process of excluding articles with specific reasons is presented in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

ObjectiveThis meta-analysis aimed to comprehensively examine the relationship between the clinicopathological and demographical characteristics and ALK rearrangements in patients with non-small cell lung cancer (NSCLC).Methods and Main FindingsIn total, 62 qualified articles including 1178 ALK rearranged cases from 20541 NSCLC patients were analyzed, and the data were extracted independently by two investigators. NSCLC patients with ALK rearrangements tended to be younger than those without (mean difference: −7.16 years; 95% confidence interval (95% CI): −9.35 to −4.96; P<0.00001), even across subgroups by race. Compared with female NSCLC patients, the odds ratio (OR) of carrying ALK rearrangements was reduced by 28% (95% CI: 0.58–0.90; P = 0.004) in males, and this reduction was potentiated in Asians, yet in opposite direction in Caucasians. Likewise, smokers were less likely to have ALK rearrangements than never-smokers (OR = 0.33; 95% CI: 0.25–0.44; P<0.00001), even in race-stratified subgroups. Moreover, compared with NSCLC patients with tumor stage IV, ALK rearrangements were underrepresented in those with tumor stage I–III (OR = 0.58; 95% CI: 0.44–0.78; P = 0.0002). Patients with lung adenocarcinomas had a significantly higher rate of ALK rearrangements (7.2%) than patients with non-adenocarcinoma (2.0%) (OR = 2.25; 95% CI: 1.54–3.27; P<0.0001).ConclusionOur findings demonstrate that ALK rearrangements tended to be present in NSCLC patients with no smoking habit, younger age and tumor stage IV. Moreover, race, age, gender, smoking status, tumor stage and histology might be potential sources of heterogeneity.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Access to crizotinib would almost make one hope that the patient with advanced NSCLC has a wild-type EGFR and falls into the minority (2.7%) with ALK mutation. [5] Parikh P, Puri T…”

Section: Lcc-a Symposium: Editorialmentioning

confidence: 99%

“…The minisymposium by the Lung Cancer Consortium: Asia on the molecular biology of lung cancer in this issue of the Indian Journal of Cancer (IJC) is proof to support this, with collective data of more than 2,500 patients with NSCLC. [2][3][4][5][6] Lung cancer is the commonest malignancy globally as well as in India. [7] Its mortality is also very high.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Personalized medicine: Lung Cancer leads the way

Parikh¹,

Puri²

2013

Indian J Cancer

View full text Add to dashboard Cite

“…1 Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3 to 5% of NSCLCs. 2 Crizotinib is a first-generation orally active ALK inhibitor, which has revolutionized the treatment of ALK-positive NSCLC since receiving Food and Drug Administration approval in November 2013.…”

Section: Introductionmentioning

confidence: 99%

Crizotinib-Associated Renal Cysts: A Case Series

Suman

Patra

Janu

et al. 2019

Journal of Gastrointestinal and Abdominal Radiology

View full text Add to dashboard Cite

Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor, used as a targeted chemotherapeutic agent in ALK-positive cases of nonsmall cell lung carcinoma. Although uncommon, it may be associated with the formation of new renal cysts, which may be simple or complex, or the enlargement of preexisting simple renal cysts or their transformation into complex cysts. These cysts usually regress partially or completely but may rarely enlarge over time or get complicated by infection or abscess formation. Such cases may even require dose reduction or withholding crizotinib. Although documented in clinical literature, this entity is not well known among radiologists. Knowledge of this entity helps in preventing erroneous diagnosis of the new kidney “lesion” as metastasis or disease progression and avoids an unnecessary biopsy. We describe a series of four cases which developed complex renal cysts during treatment with crizotinib to demonstrate this point.

show abstract

A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectives

Cited by 31 publications

References 24 publications

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis

Personalized medicine: Lung Cancer leads the way

Crizotinib-Associated Renal Cysts: A Case Series

Contact Info

Product

Resources

About